April 11, 2022 — Radiation to the heart during treatment for locally advanced lung cancer is associated with an increased risk of major adverse cardiac events within the first two years following treatment. The higher the cardiac dose exposure, the higher the risk of a cardiac event.

April 8, 2022 – Patients taking renin-angiotensin-aldosterone system inhibitor (RAASi) medications for heart failure had significantly lower blood potassium levels when taking patiromer—a drug that helps to prevent the body from absorbing too much potassium—compared with a placebo, in a study presented at the American College of Cardiology’s 71st Annual Scientific Session.

April 7, 2022 – While there are effective therapies to reduce the risk of heart disease by lowering low-density lipoprotein (LDL), or “bad” cholesterol, and other lipids, to date there are no approved treatments to lower lipoprotein(a), a lesser-known driver of heart disease risk.

April 7, 2022 – Patients treated with the blood thinner edoxaban for six months after a heart valve replacement procedure experienced fewer symptomless blood clots inside the heart valve replacement than patients who were treated with two antiplatelet drugs, according to data presented at the American College of Cardiology’s 71^st Annual S

April 7, 2022 – Among patients undergoing non-cardiac surgery who were also on blood pressure medications, a multifaceted strategy to try to keep their blood pressure from dropping to a potentially dangerous low level immediately before, during and for up to two days after surgery made no difference in the rates of major cardiovascular events in the 30 days following surgery. The research was presented at the American College of Cardiology’s 71st Annual Scientific Session.